KRAS and cholangiocarcinoma: A recent study revealed that KRAS and TP53 mutations were relatively common in cholangiocarcinoma, particularly in extrahepatic cholangiocarcinoma, while IDH1/2 and BRAF mutations were considerably more prevalent in ICC [31].